Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial ribosome-associated GTPase 2 (MTG2), also known as GTPBP5, is a mitochondrial Obg-family GTPase essential for the late stages of large mitochondrial ribosomal subunit (mtLSU) assembly[1][2]. MTG2 functions as a molecular switch, regulating critical mitochondrial processes including ribosome biogenesis and protein synthesis[1][2]. It directly interacts with 16S rRNA and specific ribosomal proteins and plays a checkpoint role by coordinating with assembly factors to ensure only mature ribosomal subunits become part of the active ribosome[1]. Loss of MTG2 impairs mitochondrial protein synthesis and overall energy metabolism, with pathological consequences in high-energy tissues[2]. MTG2 is evolutionarily conserved and specifically associated with mitochondria, operating as a peripheral protein of the inner mitochondrial membrane[3]. Key points: - MTG2 is not considered a primary therapeutic target (such as a receptor, transporter, or typical drug target) in current literature; its dysfunction has pathogenic consequences, but no drugs or direct modulators are reported[1][2]. - Main role: Late-stage assembly and maturation of the mitochondrial large ribosomal subunit, crucial for mitochondrial protein synthesis and energy production[1][2][3]. - Pathology: Mutations or dysfunction in MTG2 can contribute to mitochondrial diseases, especially those affecting energy-demanding organs[2]. - Family/Classification: Belongs to the Obg family of GTPases, classified enzymatically as a GTPase and as a mitochondrial ribosome assembly factor[1][2][3]. If you require fields such as interacting drugs, mechanism of action, biomarkers, or safety concerns specifically for drug development, current sources do not report them for MTG2. The gene's disruption affects mitochondrial function, but it is not an established drug target at present[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial ribosome-associated GTPase 2 (MTG2).